In this episode Sacha and Matthew talk about the fascinating psychedelic brews from ancient history. They question if our account of Christian history is correct, and even suggest that psychedelics are in part responsible for the very concept of communing with God. Did Moses really see a burning bush or was he just tripping? Tune in and find out!
In this interview, David Flores sits down with Dr. Mike…
Maya Health’s Co-Founder and CEO, David Champion, discusses the importance of data and analytics in the growing psychedelic community.
Two doses of psilocybin over a period of eight weeks significantly reduced alcohol use and cravings for alcoholics. That’s according to early results of a New York University phase 2 study.
Numinus Acquiring Novamind in First Major Psychedelics Merger
Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd: www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20
Not only will this be your chance to meet me, but also the legendary Paul Stamets!
Join our Newsletter (scroll to the bottom of the page and sign up): https://psychedelicspotlight.com/psyc…
Follow us on Twitter:
James: @Psy_Invest
Maria: @psy_holy
The Psychedelic Investor: @PsycInvestor
Psychedelic Spotlight: @PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
Back to Numinus
This acquisition will make Numinus the psychedelic medicines company with the highest revenue, though of course there is still a long road to profitability.
Psychedelic stock investors woke up to some major news today: Numinus Wellness (TSX: NUMI) (OTCQX: NUMIF) announced that they are acquiring Novamind Inc. (CSE: NM) (OTCQB: NVMDF).
The acquisition will be done in stock, and shareholders of Novamind will receive 0.84 of a common share of Numinus per Novamind share held, implying an offer price of $0.44 per Novamind share. This means Numinus is offering a premium of 51% to Novamind shareholders, based on the 20-day volume-weighted average price of their stock. When the transaction is completed, Novamind shareholders will own around 18% of Numinus.
If you currently hold Novamind stock, you do not need to do anything. When the transaction is finalized, each Novamind share you own will automatically be transformed into 0.84 of a Numinus share.
#Numinus #NovaMind #psychedelicStocks
If you’re looking for a psychedelic poem to start your day with, “Death of a Former Self” offers plenty of food for thought.
CBD and psychedelics, in particular, offer not only relaxation but also the potential to reduce pain or treat other ailments. Here is what you need to know about CBD and psychedelics: interactions and research.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.
